Intralesional Tetracycline Injection in the Treatment of Chalazia (TET)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01763437|
Recruitment Status : Withdrawn (Investigator left the institution)
First Posted : January 8, 2013
Last Update Posted : January 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Chalazia Chalazion||Drug: Tetracycline||Early Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Intralesional Tetracycline Injection in the Treatment of Chalazia|
|Study Start Date :||March 2014|
|Estimated Primary Completion Date :||March 2015|
|Estimated Study Completion Date :||March 2015|
No Intervention: Observation
30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.
30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.
Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
- Lesion size [ Time Frame: 4 weeks ]The size of the lesion will be measured as well as photographed. Photographs will be reviewed by a masked chalazion photograph reviewer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01763437
|United States, Ohio|
|Cleveland Clinic Cole Eye Institute|
|Cleveland, Ohio, United States, 44145|
|Principal Investigator:||Julian D Perry, M.D.||Cleveland Clinic Cole Eye Institute|